{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04884035",
            "orgStudyIdInfo": {
                "id": "CC-220-DLBCL-001"
            },
            "secondaryIdInfos": [
                {
                    "id": "2020-005705-71",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Celgene",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma",
            "officialTitle": "A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-safety-and-efficacy-of-iberdomide-cc-and-cc-combined-with-r-chop-to-treat-lymphoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-09-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-07-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-02-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-05-07",
            "studyFirstSubmitQcDate": "2021-05-07",
            "studyFirstPostDateStruct": {
                "date": "2021-05-12",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Celgene",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP-21); CC-220 and R-CHOP-21 or CC-99282 and R-CHOP-21. Part 1 will be followed by a randomized dose expansion (Part 2) with CC-220 and/or CC-99282 at the Recommended Phase 2 Dose (RP2D) in combination with R-CHOP-21. A polatuzumab-R-CHP regimen in combination with CC-220 or CC-99282 will be explored with the addition of a new cohort only after the RP2D for the CC-220 and/or CC-99282 and R-CHOP-21 combination has been defined."
        },
        "conditionsModule": {
            "conditions": [
                "Lymphoma, B-Cell"
            ],
            "keywords": [
                "Iberdomide",
                "CC-220",
                "CC-99282",
                "Phase 1",
                "B-Cell Lymphoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 174,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Administration of CC-220 with R-CHOP-21",
                    "type": "EXPERIMENTAL",
                    "description": "CC-220 to be administered orally in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP-21) for 6 cycles of treatment",
                    "interventionNames": [
                        "Drug: CC-220",
                        "Drug: Rituximab",
                        "Drug: Cyclophosphamide",
                        "Drug: Doxorubicin",
                        "Drug: Vincristine",
                        "Drug: Prednisone"
                    ]
                },
                {
                    "label": "Administration of CC-99282 with R-CHOP-21",
                    "type": "EXPERIMENTAL",
                    "description": "CC-99282 to be administered orally in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP-21) for 6 cycles of treatment",
                    "interventionNames": [
                        "Drug: Rituximab",
                        "Drug: Cyclophosphamide",
                        "Drug: Doxorubicin",
                        "Drug: Vincristine",
                        "Drug: Prednisone",
                        "Drug: CC-99282"
                    ]
                },
                {
                    "label": "Administration of CC-220 with polatuzumab-R-CHP",
                    "type": "EXPERIMENTAL",
                    "description": "CC-220 to be administered orally in combination with Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (polatuzumab-R-CHP) for 6 cycles of treatment",
                    "interventionNames": [
                        "Drug: CC-220",
                        "Drug: Cyclophosphamide",
                        "Drug: Doxorubicin",
                        "Drug: Prednisone",
                        "Drug: Polatuzumab vedotin",
                        "Drug: Rituximab"
                    ]
                },
                {
                    "label": "Administration of CC-99282 with polatuzumab-R-CHP",
                    "type": "EXPERIMENTAL",
                    "description": "CC-99282 to be administered orally in combination with Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (polatuzumab-R-CHP) for 6 cycles of treatment",
                    "interventionNames": [
                        "Drug: Cyclophosphamide",
                        "Drug: Doxorubicin",
                        "Drug: Prednisone",
                        "Drug: CC-99282",
                        "Drug: Polatuzumab vedotin",
                        "Drug: Rituximab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "CC-220",
                    "description": "CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.",
                    "armGroupLabels": [
                        "Administration of CC-220 with R-CHOP-21",
                        "Administration of CC-220 with polatuzumab-R-CHP"
                    ],
                    "otherNames": [
                        "Iberdomide",
                        "BMS-986382"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Rituximab",
                    "description": "Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles",
                    "armGroupLabels": [
                        "Administration of CC-220 with R-CHOP-21",
                        "Administration of CC-99282 with R-CHOP-21"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles",
                    "armGroupLabels": [
                        "Administration of CC-220 with R-CHOP-21",
                        "Administration of CC-220 with polatuzumab-R-CHP",
                        "Administration of CC-99282 with R-CHOP-21",
                        "Administration of CC-99282 with polatuzumab-R-CHP"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Doxorubicin",
                    "description": "Doxorubicin 50 mg/m2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles",
                    "armGroupLabels": [
                        "Administration of CC-220 with R-CHOP-21",
                        "Administration of CC-220 with polatuzumab-R-CHP",
                        "Administration of CC-99282 with R-CHOP-21",
                        "Administration of CC-99282 with polatuzumab-R-CHP"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Vincristine",
                    "description": "Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) IV intravenous on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles",
                    "armGroupLabels": [
                        "Administration of CC-220 with R-CHOP-21",
                        "Administration of CC-99282 with R-CHOP-21"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Prednisone",
                    "description": "Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles",
                    "armGroupLabels": [
                        "Administration of CC-220 with R-CHOP-21",
                        "Administration of CC-220 with polatuzumab-R-CHP",
                        "Administration of CC-99282 with R-CHOP-21",
                        "Administration of CC-99282 with polatuzumab-R-CHP"
                    ],
                    "otherNames": [
                        "Prednisolone"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "CC-99282",
                    "description": "CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.",
                    "armGroupLabels": [
                        "Administration of CC-99282 with R-CHOP-21",
                        "Administration of CC-99282 with polatuzumab-R-CHP"
                    ],
                    "otherNames": [
                        "BMS-986369"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Polatuzumab vedotin",
                    "description": "Polatuzumab vedotin 1.8 mg/kg on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles",
                    "armGroupLabels": [
                        "Administration of CC-220 with polatuzumab-R-CHP",
                        "Administration of CC-99282 with polatuzumab-R-CHP"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Rituximab",
                    "description": "Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles",
                    "armGroupLabels": [
                        "Administration of CC-220 with polatuzumab-R-CHP",
                        "Administration of CC-99282 with polatuzumab-R-CHP"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum Tolerated Dose (MTD) - Part 1",
                    "description": "Frequency of dose-limiting toxicities (DLT) associated with addition of iberdomide (CC-220) to R-CHOP-21 therapy and the addition of CC-99282 to R-CHOP-21 therapy",
                    "timeFrame": "During the first 2 cycles of treatment (each cycle is 21 days)"
                },
                {
                    "measure": "Recommended Phase 2 Dose (RP2D) - Part 1",
                    "description": "Defined as the dose that will be selected for dose expansion based on MTD",
                    "timeFrame": "During the first cycle of treatment (each cycle is 21 days)"
                },
                {
                    "measure": "Safety and tolerability of CC-220 and CC-99282 at RP2D - Part 2",
                    "description": "AEs evaluated using NCI CTCAE criteria, v. 5.0, including treatment -emergent adverse events (TEAEs) and laboratory assessments",
                    "timeFrame": "From the first dose of any IP until 28 days after the last dose of IP"
                },
                {
                    "measure": "Maximum Tolerated Dose (MTD) - Part 2A",
                    "description": "Frequency of DLTs associated with addition of iberdomide (CC-220) to polatuzumab-R-CHP therapy and the addition of CC-99282 to polatuzumab-R-CHP therapy",
                    "timeFrame": "During the first cycle of treatment (each cycle is 21 days)"
                },
                {
                    "measure": "Recommended Phase 2 Dose (RP2D) - Part 2A",
                    "description": "Defined as the dose that will be selected for dose expansion based on MTD",
                    "timeFrame": "During the first cycle of treatment (each cycle is 21 days)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Best overall response rate (ORR)",
                    "description": "The proportion of participants with best overall response achieved during the study as either Complete Response or Partial Response before subsequent anti-lymphoma therapy",
                    "timeFrame": "Up to 4 years"
                },
                {
                    "measure": "Complete Metabolic Response Rate (CMRR)",
                    "description": "The proportion of participants experiencing complete metabolic response (CMR) before receiving any subsequent anti-lymphoma therapy",
                    "timeFrame": "Up to 4 years"
                },
                {
                    "measure": "Time to Response (TTR)",
                    "description": "The time from entry to the study (enrollment date for Part 1 and randomization date for Part 2) to the date of first documented response (\u2265 PR)",
                    "timeFrame": "Up to 4 years"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "description": "The time from the earliest date of documented response (\u2265 PR) to the first occurrence of relapse or progression",
                    "timeFrame": "Up to 4 years"
                },
                {
                    "measure": "Progression-free Survival (PFS)",
                    "description": "The time from entry to the study (enrollment date for Part 1 and randomization date for Part 2) to the first occurrence of disease progression or death from any cause",
                    "timeFrame": "Up to 4 years"
                },
                {
                    "measure": "Overall Survival (OS)",
                    "description": "The time from entry to the study (enrollment date for Part 1 and randomization date for Part 2) to death from any cause",
                    "timeFrame": "Up to 4 years"
                },
                {
                    "measure": "Pharmacokinetics - Cmax for CC-220",
                    "description": "Maximum plasma concentration of drug",
                    "timeFrame": "At Cycle 1 Day 7, Cycle 1 Day 15, and Cycle 2 Day 7 (each cycle is 21 days)"
                },
                {
                    "measure": "Pharmacokinetics - Ctrough for CC-220",
                    "description": "Minimum or trough concentration",
                    "timeFrame": "At Cycle 1 Day 7, Cycle 1 Day 15, and Cycle 2 Day 7 (each cycle is 21 days"
                },
                {
                    "measure": "Pharmacokinetics - Tmax for CC-220",
                    "description": "Time to maximum plasma concentration",
                    "timeFrame": "At Cycle 1 Day 7, Cycle 1 Day 15, and Cycle 2 Day 7 (each cycle is 21 days"
                },
                {
                    "measure": "Pharmacokinetics - Cmax for CC-99282",
                    "description": "Maximum plasma concentration",
                    "timeFrame": "At Cycle 1 Day 7, Cycle 1 Day 15, and Cycle 2 Day 7 (each cycle is 21 days"
                },
                {
                    "measure": "Pharmacokinetics - Ctrough for CC-99282",
                    "description": "Minimum or trough concentration",
                    "timeFrame": "At Cycle 1 Day 7, Cycle 1 Day 15, and Cycle 2 Day 7 (each cycle is 21 days"
                },
                {
                    "measure": "Pharmacokinetics - Tmax for CC-99282",
                    "description": "Time to maximum plasma concentration",
                    "timeFrame": "At Cycle 1 Day 7, Cycle 1 Day 15, and Cycle 2 Day 7 (each cycle is 21 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants must satisfy the following criteria to be enrolled in the study:\n\n  1. Is \u2265 18 years of age at the time of signing the informed consent form (ICF).\n  2. Participant has histologically confirmed (per local evaluation) diagnosis of de novo, previously untreated, a-BCL according to 2016 WHO classification.\n  3. Participant has International Prognostic Index (IPI) score 0-5 in Part 1 and IPI 2-5 in Part 2. For the CELMoD and polatuzumab-R-CHP cohort, the subject must also have IPI score 0 to 5 in Part 2A and IPI 2 to 5 in Part 2B.\n  4. Participants must have measurable disease defined by at least one FDG-avid lesion for FDG-avid subtype and one bi-dimensionally measurable (\\> 1.5 cm in longest diameter) disease by computed tomography (CT) or magnetic resonance imaging (MRI), as defined by the Lugano classification (Cheson, 2014).\n  5. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n  6. Participants must have the following laboratory values:\n\n     1. Absolute neutrophil count (ANC) \u2265 1.5 x 109/L or \u2265 1.0 x 109/L in case of documented bone marrow involvement (\\> 50% or tumor cells), without growth factor support for 7 days (14 days if peg-G-CSF)\n     2. Hemoglobin (Hb) \u2265 8 g/dL\n     3. Platelets (PLT) \u2265 75 x 109/L or \u2265 50 x 109/L in case of documented bone marrow involvement (\\>50% or tumor cells), without transfusion for 7 days\n     4. Aspartate aminotransferase / serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase / serum glutamate pyruvic transaminase (ALT/SGPT) \u2264 2.5 x upper limit of normal (ULN). In the case of documented liver involvement by lymphoma, ALT/SGPT and AST/SGOT must be \u2264 5.0 x ULN.\n     5. Serum total bilirubin \u2264 2.0 mg/dL except in cases of Gilbert's syndrome, then \u2264 5.0 mg/dl. Subjects receiving polatuzumab vedotin must have serum total bilirubin \\< 1.5 \u00d7 ULN (26 \u03bcmol/L) (corresponding to mild degree as per National Cancer Institute Organ Dysfunction Working Group \\[NCI ODWG\\] criteria) except in cases of Gilbert's syndrome, then \u2264 3.0 mg/dl (51 \u03bcmol/L).\n     6. Estimated serum creatinine clearance (CrCl) of \u2265 50 mL/min using the modification of diet in renal disease (MDRD) formula.\n  7. All participants must:\n\n     1. Have an understanding that the study drug could have a potential teratogenic risk.\n     2. Agree to follow all requirements defined in the Pregnancy Prevention Program for CC-220 or CC-99282 Pregnancy Prevention Plan for Participants in Clinical trials.\n  8. Females of childbearing potential (FCBP) must:\n\n     a. Have two negative pregnancy tests as verified by the investigator prior to starting study therapy.\n  9. Male participants must:\n\n     1. Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study.\n\nExclusion Criteria:\n\n* The presence of any of the following will exclude a participant from enrollment:\n\n  1. Any significant medical condition, active infection (including SARS-CoV-2 suspected or confirmed), laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.\n  2. Any condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study.\n  3. Any other subtype of lymphoma.\n  4. Documented or suspected CNS involvement by lymphoma.\n  5. Persistent diarrhea or malabsorption \u2265 Grade 2 (NCI CTCAE v5.0), despite medical management.\n  6. Peripheral neuropathy \u2265 Grade 2 (NCI CTCAE v5.0).\n  7. Subjects with a history of progressive multifocal leukoencephalopathy.\n  8. Chronic systemic immunosuppressive therapy or corticosteroids\n  9. Impaired cardiac function or clinically significant cardiac disease, including any of the following:\n\n     a. Left ventricular ejection fraction (LVEF) \\< 45% as determined by multigated acquisition (MUGA) scan or echocardiogram (ECHO)\n  10. Major surgery \u2264 2 weeks prior to starting CC-220 or CC-99282; participant must have recovered from any clinically significant effects of recent surgery.\n  11. Any condition causing inability to swallow tablets.\n  12. Known seropositivity for or active viral infection with human immunodeficiency virus (HIV)\n  13. Known chronic active hepatitis B (hepatitis B virus surface antigen \\[HBsAg\\] positive and/or hepatitis B core antibody \\[anti-HBc\\] positive with viral DNA positive) or C (positive serology requiring treatment and/or with evidence of liver damage) infection\n  14. History of other malignancy, unless being free of the disease for \u2265 3 years; exceptions to the \u2265 3-year time limit include history of the following:\n\n      1. Localized nonmelanoma skin cancer\n      2. Carcinoma in situ of the cervix\n      3. Carcinoma in situ of the breast\n      4. Incidental histologic finding of prostate cancer (T1a or T1b as per Tumor Node Metastasis \\[TNM\\] staging system) or prostate cancer that has been treated with curative intent.\n  15. Hypersensitivity to the active substance or to murine proteins, or to any of the other excipients of rituximab or polatuzumab vedotin.\n  16. Known hypersensitivity to any component of CHOP/CHP regimen.\n  17. Known allergy to thalidomide, pomalidomide, or lenalidomide.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "BMS Study Connect Contact Center www.BMSStudyConnect.com",
                    "role": "CONTACT",
                    "phone": "855-907-3286",
                    "email": "Clinical.Trials@bms.com"
                },
                {
                    "name": "First line of the email MUST contain the NCT # and Site #.",
                    "role": "CONTACT"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Bristol-Myers Squibb",
                    "affiliation": "Bristol-Myers Squibb",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic - Arizona",
                    "status": "RECRUITING",
                    "city": "Scottsdale",
                    "state": "Arizona",
                    "zip": "85259",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Javier Munoz, Site 154",
                            "role": "CONTACT",
                            "phone": "480-301-8000"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.50921,
                        "lon": -111.89903
                    }
                },
                {
                    "facility": "Mayo Clinic - Jacksonville",
                    "status": "WITHDRAWN",
                    "city": "Jacksonville",
                    "state": "Florida",
                    "zip": "32224",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.33218,
                        "lon": -81.65565
                    }
                },
                {
                    "facility": "Mayo Clinic Jacksonville - PPDS",
                    "status": "RECRUITING",
                    "city": "Jacksonville",
                    "state": "Florida",
                    "zip": "32224",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Muhamad Alhaj Moustafa, Site 160",
                            "role": "CONTACT",
                            "phone": "904-953-2000"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.33218,
                        "lon": -81.65565
                    }
                },
                {
                    "facility": "University Of Kansas Medical Center",
                    "status": "RECRUITING",
                    "city": "Kansas City",
                    "state": "Kansas",
                    "zip": "66160",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Marc Hoffmann, Site 159",
                            "role": "CONTACT",
                            "phone": "913-574-2650"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.11417,
                        "lon": -94.62746
                    }
                },
                {
                    "facility": "Mayo Clinic - Rochester",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905-0001",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Grzegorz Nowakowski, Site 152",
                            "role": "CONTACT",
                            "phone": "507-284-2511"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                },
                {
                    "facility": "University of Nebraska - Fred and Pamela Buffet Center",
                    "status": "RECRUITING",
                    "city": "Omaha",
                    "state": "Nebraska",
                    "zip": "68198",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Matthew Lunning, Site 151",
                            "role": "CONTACT",
                            "phone": "402-559-7164"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.25626,
                        "lon": -95.94043
                    }
                },
                {
                    "facility": "Roswell Park Cancer Institute",
                    "status": "WITHDRAWN",
                    "city": "Buffalo",
                    "state": "New York",
                    "zip": "14263",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.88645,
                        "lon": -78.87837
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77003",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jason Westin, Site 155",
                            "role": "CONTACT",
                            "phone": "713-792-3750"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Local Institution - 501",
                    "status": "COMPLETED",
                    "city": "Adelaide",
                    "state": "South Australia",
                    "zip": "5000",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -34.92866,
                        "lon": 138.59863
                    }
                },
                {
                    "facility": "Local Institution - 503",
                    "status": "COMPLETED",
                    "city": "Perth",
                    "zip": "WA 6000",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -31.95224,
                        "lon": 115.8614
                    }
                },
                {
                    "facility": "Local Institution - 502",
                    "status": "WITHDRAWN",
                    "city": "Waratah",
                    "zip": "NSW",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -32.90667,
                        "lon": 151.72647
                    }
                },
                {
                    "facility": "Evangelismos General Hospital of Athens",
                    "status": "RECRUITING",
                    "city": "Athens",
                    "zip": "10676",
                    "country": "Greece",
                    "contacts": [
                        {
                            "name": "Maria Bouzani, Site 702",
                            "role": "CONTACT",
                            "phone": "00306977318242"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.97945,
                        "lon": 23.71622
                    }
                },
                {
                    "facility": "General Hospital of Athens \"Laiko\"",
                    "status": "RECRUITING",
                    "city": "Athens",
                    "zip": "11 527",
                    "country": "Greece",
                    "contacts": [
                        {
                            "name": "Theodoros Vassilakopoulos, Site 704",
                            "role": "CONTACT",
                            "phone": "+00302107456902"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.97945,
                        "lon": 23.71622
                    }
                },
                {
                    "facility": "Attikon University General Hospital",
                    "status": "RECRUITING",
                    "city": "Athens",
                    "zip": "12464",
                    "country": "Greece",
                    "contacts": [
                        {
                            "name": "Vassiliki Pappa, Site 701",
                            "role": "CONTACT",
                            "phone": "+302105831000 000 00"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.97945,
                        "lon": 23.71622
                    }
                },
                {
                    "facility": "Local Institution - 703",
                    "status": "WITHDRAWN",
                    "city": "Patras",
                    "zip": "26500",
                    "country": "Greece",
                    "geoPoint": {
                        "lat": 38.24444,
                        "lon": 21.73444
                    }
                },
                {
                    "facility": "Georgios Papanikolaou General Hospital of Thessaloniki",
                    "status": "RECRUITING",
                    "city": "Thessaloniki",
                    "zip": "57010",
                    "country": "Greece",
                    "contacts": [
                        {
                            "name": "Ioanna Sakellari, Site 700",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.64361,
                        "lon": 22.93086
                    }
                },
                {
                    "facility": "Local Institution - 300",
                    "status": "COMPLETED",
                    "city": "Seoul",
                    "zip": "06351",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Local Institution - 302",
                    "status": "COMPLETED",
                    "city": "Seoul",
                    "zip": "138-736",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Local Institution - 301",
                    "status": "COMPLETED",
                    "city": "Seoul",
                    "zip": "3080",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Local Institution - 601",
                    "status": "RECRUITING",
                    "city": "Gdansk",
                    "zip": "80-952",
                    "country": "Poland",
                    "contacts": [
                        {
                            "name": "Site 601",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 54.35205,
                        "lon": 18.64637
                    }
                },
                {
                    "facility": "MCM Krakow - PRATIA - PPDS",
                    "status": "RECRUITING",
                    "city": "Krakow",
                    "zip": "30-727",
                    "country": "Poland",
                    "contacts": [
                        {
                            "name": "Wojciech Jurczak, Site 600",
                            "role": "CONTACT",
                            "phone": "+48602338290"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.06143,
                        "lon": 19.93658
                    }
                },
                {
                    "facility": "Centrum Medyczne Pratia Poznan",
                    "status": "RECRUITING",
                    "city": "Poznan",
                    "zip": "60-185",
                    "country": "Poland",
                    "contacts": [
                        {
                            "name": "Michal Kwiatek, Site 605",
                            "role": "CONTACT",
                            "phone": "48793602210"
                        }
                    ],
                    "geoPoint": {
                        "lat": 52.40692,
                        "lon": 16.92993
                    }
                },
                {
                    "facility": "Local Institution - 0706",
                    "status": "WITHDRAWN",
                    "city": "Poznan",
                    "zip": "60-185",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 52.40692,
                        "lon": 16.92993
                    }
                },
                {
                    "facility": "Local Institution - UNK0706",
                    "status": "WITHDRAWN",
                    "city": "Poznan",
                    "zip": "60-185",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 52.40692,
                        "lon": 16.92993
                    }
                },
                {
                    "facility": "SP ZOZ Szpital Uniwersytecki w Krakowie",
                    "status": "RECRUITING",
                    "city": "Slomniki",
                    "zip": "32-090",
                    "country": "Poland",
                    "contacts": [
                        {
                            "name": "Dagmara Zimowska-Curylo, Site 603",
                            "role": "CONTACT",
                            "phone": "+48122954139"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.24012,
                        "lon": 20.08224
                    }
                },
                {
                    "facility": "Local Institution - 602",
                    "status": "RECRUITING",
                    "city": "Warsaw",
                    "zip": "02-781",
                    "country": "Poland",
                    "contacts": [
                        {
                            "name": "Site 602",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 52.22977,
                        "lon": 21.01178
                    }
                },
                {
                    "facility": "Local Institution - 604",
                    "status": "RECRUITING",
                    "city": "Wroclaw",
                    "zip": "50-367",
                    "country": "Poland",
                    "contacts": [
                        {
                            "name": "Site 604",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.1,
                        "lon": 17.03333
                    }
                },
                {
                    "facility": "Hospital Universitari Germans Trias i Pujol ICO Badalona",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08916",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Juan Manuel Sancho, Site 201",
                            "role": "CONTACT",
                            "phone": "+34934978987"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Local Institution - 204",
                    "status": "WITHDRAWN",
                    "city": "Madrid",
                    "zip": "28028",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "H. Virgen de la Victoria",
                    "status": "RECRUITING",
                    "city": "M\u00e1laga",
                    "zip": "29010",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Antonio Rueda-Dom\u00ednguez, Site 203",
                            "role": "CONTACT",
                            "phone": "+34951032467 00 000"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.72016,
                        "lon": -4.42034
                    }
                },
                {
                    "facility": "Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca",
                    "status": "RECRUITING",
                    "city": "Salamanca",
                    "zip": "37007",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Alejandro Martin Garcia-Sancho, Site 200",
                            "role": "CONTACT",
                            "phone": "+34980548200"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.96882,
                        "lon": -5.66388
                    }
                },
                {
                    "facility": "Local Institution - 403",
                    "status": "RECRUITING",
                    "city": "Taichung",
                    "zip": "40447",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "name": "Site 403",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 24.1469,
                        "lon": 120.6839
                    }
                },
                {
                    "facility": "Local Institution - 402",
                    "status": "RECRUITING",
                    "city": "Taichung",
                    "zip": "407219",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "name": "Site 402",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 24.1469,
                        "lon": 120.6839
                    }
                },
                {
                    "facility": "National Taiwan University Hospital",
                    "status": "RECRUITING",
                    "city": "Taipei",
                    "zip": "100229",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "name": "Tai-Chung Huang, Site 400",
                            "role": "CONTACT",
                            "phone": "+886972651392"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.04776,
                        "lon": 121.53185
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "BMS Clinical Trial Information",
                    "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"
                },
                {
                    "label": "FDA Safety Alerts and Recalls",
                    "url": "http://www.fda.gov/MEDWATCH/safety.htm"
                },
                {
                    "label": "BMS Clinical Trial Patient Recruiting",
                    "url": "https://www.bmsstudyconnect.com/content/studyconnect/us/en/clinical-trials/NCT04884035.html"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Information relating to our policy on data sharing and the process for requesting data can be found at the following link:\n\nhttps://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR",
                "ANALYTIC_CODE"
            ],
            "timeFrame": "See Plan Description",
            "accessCriteria": "See Plan Description",
            "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000016393",
                    "term": "Lymphoma, B-Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18828",
                    "name": "Lymphoma, B-Cell",
                    "asFound": "Lymphoma, B-Cell",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3724",
                    "name": "Aggression",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T640",
                    "name": "B-cell Lymphoma",
                    "asFound": "Lymphoma, B-Cell",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011241",
                    "term": "Prednisone"
                },
                {
                    "id": "D000011239",
                    "term": "Prednisolone"
                },
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "D000069283",
                    "term": "Rituximab"
                },
                {
                    "id": "D000004317",
                    "term": "Doxorubicin"
                },
                {
                    "id": "D000014750",
                    "term": "Vincristine"
                },
                {
                    "id": "C000600736",
                    "term": "Polatuzumab vedotin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000903",
                    "term": "Antibiotics, Antineoplastic"
                },
                {
                    "id": "D000059005",
                    "term": "Topoisomerase II Inhibitors"
                },
                {
                    "id": "D000059003",
                    "term": "Topoisomerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                },
                {
                    "id": "D000005938",
                    "term": "Glucocorticoids"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000018796",
                    "term": "Immunoconjugates"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7492",
                    "name": "Doxorubicin",
                    "asFound": "Cognitive",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17495",
                    "name": "Vincristine",
                    "asFound": "Phase I",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14121",
                    "name": "Prednisone",
                    "asFound": "Prospective",
                    "relevance": "HIGH"
                },
                {
                    "id": "M373",
                    "name": "Rituximab",
                    "asFound": "Infusion",
                    "relevance": "HIGH"
                },
                {
                    "id": "M289652",
                    "name": "Polatuzumab vedotin",
                    "asFound": "Interferon beta-",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11749",
                    "name": "Methylprednisolone",
                    "relevance": "LOW"
                },
                {
                    "id": "M1833",
                    "name": "Methylprednisolone Acetate",
                    "relevance": "LOW"
                },
                {
                    "id": "M11750",
                    "name": "Methylprednisolone Hemisuccinate",
                    "relevance": "LOW"
                },
                {
                    "id": "M14120",
                    "name": "Prednisolone",
                    "asFound": "Determined",
                    "relevance": "HIGH"
                },
                {
                    "id": "M229449",
                    "name": "Prednisolone acetate",
                    "relevance": "LOW"
                },
                {
                    "id": "M211887",
                    "name": "Prednisolone hemisuccinate",
                    "relevance": "LOW"
                },
                {
                    "id": "M248881",
                    "name": "Prednisolone phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M227339",
                    "name": "Liposomal doxorubicin",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4224",
                    "name": "Antibiotics, Antitubercular",
                    "relevance": "LOW"
                },
                {
                    "id": "M29348",
                    "name": "Topoisomerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M9047",
                    "name": "Glucocorticoids",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20855",
                    "name": "Immunoconjugates",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "AnEm",
                    "name": "Antiemetics"
                },
                {
                    "abbrev": "NeuroAg",
                    "name": "Neuroprotective Agents"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}